EUVIMEDEUVIMED entdecken
Open Access

Cobimetinib Plus Vemurafenib in Patients With Solid Tumors With BRAF Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study

Funda Meric-Bernstam iD, Michael Rothe, Pam K Mangat iD, Elizabeth Garrett-Mayer iD, Rodolfo Gutierrez, Eugene R Ahn, Timothy L Cannon iD, Steven Powell iD, John C Krauss iD, Christopher M Reynolds, Margaret von Mehren iD, Deepti Behl iD und 11 weitere

JCO Precision Oncology · 2023-09 · (7)

DOI: 10.1200/po.23.00385 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Precision Oncology, 2023-09. Verfasst von Funda Meric-Bernstam und 22 weiteren Autor:innen. Beteiligte Einrichtung: University of Texas MD Anderson Cancer Center, Houston, TX. Hauptthemen laut MEDLINE: Melanoma, Antineoplastic Agents. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE The Targeted Agent and Profiling Utilization Registry Study is a phase II basket study evaluating antitumor activity of commercially available targeted agents in patients with advanced cancers with genomic alterations known to be drug targets. The results in a cohort of patients with solid tumors with BRAF mutations treated with cobimetinib plus vemurafenib are reported. METHODS Eligible patients had measurable disease (RECIST v.1.1), Eastern Cooperative Oncology Group performance status 0-2, adequate organ function, and no standard treatment options. The primary end point was disease control (DC), defined as complete response (CR) or partial response (PR) or stable disease of at least 16-weeks duration (SD16+). Low-accruing histology-specific cohorts with BRAF mutations treated with cobimetinib plus vemurafenib were collapsed into a single histology-pooled cohort for this analysis. The results were evaluated on the basis of a one-sided exact binomial test with a null DC rate of 15% versus 35% (power, .82; α, .10). The secondary end points were objective response (OR), progression-free survival, overall survival, duration of response, duration of stable disease, and safety. RESULTS Thirty-one patients with solid tumors with BRAF mutations were enrolled. Twenty-eight patients were evaluable for efficacy. Patients had tumors with BRAF V600E (n = 26), K601E (n = 2), or other (n = 3) mutations. Two patients with CR (breast and ovarian cancers; V600E), 14 with PR (13 V600E, one N581I), and three with SD16+ (two V600E, one T599_V600insT) were observed with a DC rate of 68% ( P < .0001; one-sided 90% CI, 54 to 100) and an OR rate of 57% (95% CI, 37 to 76). Nineteen patients experienced ≥one drug-related grade 3-5 adverse event or serious adverse event including one death attributed to treatment-related kidney injury. CONCLUSION Cobimetinib plus vemurafenib showed antitumor activity in patients with advanced solid tumors with BRAF V600E mutations; additional study is warranted to confirm the antitumor activity in tumors with non-V600E BRAF mutations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaAntineoplastic AgentsHumansVemurafenibProto-Oncogene Proteins B-rafMutationAzetidinesPiperidines

Substanzen

VemurafenibProto-Oncogene Proteins B-rafAntineoplastic AgentscobimetinibAzetidinesPiperidinesBRAF protein, human

Autor:innen und Institutionen

  • University of Texas MD Anderson Cancer Center, Houston, TX.
  • American Society of Clinical Oncology, Alexandria, VA.
  • The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate, Santa Monica, CA.
  • City of Hope Chicago, Zion, IL.
  • Inova Schar Cancer Institute, Fairfax, VA.
  • Sanford Health, Sioux Falls, SD.

ORCID-Profile: Funda Meric-Bernstam, Pam K Mangat, Elizabeth Garrett-Mayer, Timothy L Cannon, Steven Powell, John C Krauss, Margaret von Mehren, Deepti Behl, Carmen J Calfa, Henry G Kaplan, Manish R Sharma, Walter J Urba, Gina N Grantham, Dominique C Hinshaw, Abigail Gregory, Susan Halabi, Richard L Schilsky

Zitieren

APA

Meric-Bernstam, F., Rothe, M., Mangat, P. K., Garrett-Mayer, E., Gutierrez, R., Ahn, E. R., Cannon, T. L., Powell, S., Krauss, J. C., Reynolds, C. M., von Mehren, M., Behl, D., Calfa, C. J., Duvivier, H. L., Kaplan, H. G., Livingston, M. B., Sharma, M. R., Urba, W. J., Grantham, G. N., …, & Schilsky, R. L. (2023). Cobimetinib Plus Vemurafenib in Patients With Solid Tumors With BRAF Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precision Oncology. https://doi.org/10.1200/po.23.00385

Vancouver

Meric-Bernstam F, Rothe M, Mangat PK, Garrett-Mayer E, Gutierrez R, Ahn ER, et al. Cobimetinib Plus Vemurafenib in Patients With Solid Tumors With BRAF Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precision Oncology. 2023. doi:10.1200/po.23.00385

BibTeX
@article{MericBernstam2023,
  author = {Meric-Bernstam, Funda and Rothe, Michael and Mangat, Pam K and Garrett-Mayer, Elizabeth and Gutierrez, Rodolfo and Ahn, Eugene R and Cannon, Timothy L and Powell, Steven and Krauss, John C and Reynolds, Christopher M and von Mehren, Margaret and Behl, Deepti and Calfa, Carmen J and Duvivier, Herbert L and Kaplan, Henry G and Livingston, Michael B and Sharma, Manish R and Urba, Walter J and Grantham, Gina N and Hinshaw, Dominique C and Gregory, Abigail and Halabi, Susan and Schilsky, Richard L},
  title = {Cobimetinib Plus Vemurafenib in Patients With Solid Tumors With BRAF Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study},
  journal = {JCO Precision Oncology},
  year = {2023},
  number = {7},
  doi = {10.1200/po.23.00385}
}
Kostenlos starten →